TLR

The Access to Advanced Health Institute Receives up to $12.7 Million to Develop Novel NanoAlum Adjuvant Formulation for Better Protection Against Tuberculosis and Pandemic Influenza

Retrieved on: 
Thursday, March 7, 2024
COVID-19, Research, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Hepatitis A, Senior, Infectious Disease Research Institute, Immune system, Toxicology, Doctor of Philosophy, Medicine, Multimedia, TLR, Government, Infection, Access, Defense, RTS, Vaccine, Notifiable disease, Shingles, Malaria, Unitary state, Respiratory syncytial virus, Formulation, Fungus, MPH, MCDC, Disease, Tuberculosis, OTA, Parasitism, HIV, Cancer

View the full release here: https://www.businesswire.com/news/home/20240307661956/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307661956/en/
    This five-year prototype project will support AAHI’s development and optimization of “NanoAlum” – a novel nanoparticle adjuvant formulation, made from aluminum salts (“alum”).
  • Alum-adjuvanted vaccines have been less effective against diseases such as tuberculosis and influenza, which are more complex to target and can be challenging to manufacture because they require special sterilization methods.
  • AAHI’s NanoAlum formulation changes the size, shape, and charge of alum particles to enhance specific immune responses for better vaccine protection against complex diseases.
  • AAHI’s prototype project for MCDC will pair the combined 3M-052 and NanoAlum formulation with tuberculosis and pandemic influenza vaccine antigens.

Our Place Celebrates 2023 Community Impact Milestones and Looks Ahead to Further Outreach in 2024

Retrieved on: 
Thursday, February 1, 2024
Our Village, NBA, MLB, Overalls, Environment, Our Place, Ageing, TLR, Montage Mountain Ski Resort, Entrepreneurship, Senior counsel, Learning, Volunteering, Organization, NFL, Tourism

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Our Place (the “Organization”), a preeminent counseling and rehabilitative organization for today's Jewish youth, reflected on its 2023 work, achievements and milestones as it looks ahead to making an even greater positive impact on the Jewish community in 2024.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Our Place (the “Organization”), a preeminent counseling and rehabilitative organization for today's Jewish youth, reflected on its 2023 work, achievements and milestones as it looks ahead to making an even greater positive impact on the Jewish community in 2024.
  • “Our 2023 milestones, achievements and statistics speak for themselves.”
    Our Place leadership would like to extend its deepest gratitude to its devoted staff and network of volunteers, who make the Organization’s great work possible, and looks forward to making an even greater community impact in 2024.
  • “We couldn’t be more proud of all that the Our Place staff and membership have accomplished together in 2023,” said Eli Verschleiser, Chairman and Co-Founder of Our Place.
  • While we’re thrilled to look back on our 2023 accomplishments, we’re already hard at work making 2024 another banner year for the organization and those it serves.

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Patient, TLR 7, Conference, Protein, Drug discovery, Food, PARP1, WRN, FDA, TLR, DNA, Therapy, Cancer, Cellular, Eikon, PARP, Toxicity, Safety, Pharmaceutical industry

“Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics.

Key Points: 
  • “Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics.
  • This program is led by Eikon with its collaboration partner, Impact Therapeutics, which is responsible for trial oversight in greater China.
  • Eikon Systems Business Unit Established: Eikon has developed a suite of instruments that permits detailed, automated characterization of protein motion in living cells.
  • An archived recording of Eikon’s presentation at the J.P. Morgan Healthcare Conference can be accessed at: www.EikonTx.com/#news .

Peregrine space launch: British-Ukrainian sends moon-bound tribute to Ukraine - ahead of ambitious moon rover launch

Retrieved on: 
Monday, January 8, 2024
Moon, Astrobotic Technology, Map, Blockchain, United Launch Alliance, COVID-19, Multimedia, Asa, TLR, Japanese destroyer Asagumo, NASA, Vulcan Centaur, Temperature, Metal, Commercial Lunar Payload Services, Communications satellite

The Spacebit Asagumo moon rover launch is scheduled within a year.

Key Points: 
  • The Spacebit Asagumo moon rover launch is scheduled within a year.
  • Spacebit is sending a Ukraine metallic embossed flag that includes a map of the country in solidarity with Ukrainian people.
  • Peregrine Mission One or the Peregrine Lunar Lander is a lunar lander built by Astrobotic Technology, that was selected through NASA's Commercial Lunar Payload Services.
  • It is scheduled to be launched January 8, 2024 by United Launch Alliance aboard a Vulcan Centaur launch vehicle.

Peregrine space launch: British-Ukrainian sends moon-bound tribute to Ukraine - ahead of ambitious moon rover launch

Retrieved on: 
Monday, January 8, 2024
Moon, Astrobotic Technology, Map, Blockchain, United Launch Alliance, COVID-19, Asa, TLR, Japanese destroyer Asagumo, NASA, Vulcan Centaur, Temperature, Metal, Commercial Lunar Payload Services, Communications satellite

The Spacebit Asagumo moon rover launch is scheduled within a year.

Key Points: 
  • The Spacebit Asagumo moon rover launch is scheduled within a year.
  • Spacebit is sending a Ukraine metallic embossed flag that includes a map of the country in solidarity with Ukrainian people.
  • Peregrine Mission One or the Peregrine Lunar Lander is a lunar lander built by Astrobotic Technology, that was selected through NASA's Commercial Lunar Payload Services.
  • It is scheduled to be launched January 8, 2024 by United Launch Alliance aboard a Vulcan Centaur launch vehicle.

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
Janus, Atopic dermatitis, Receptor (biochemistry), Sanofi, Janus kinase, Hidradenitis suppurativa, Eosinophilic esophagitis, Autoimmunity, Inflammatory bowel disease, HS, Inflammation, Lupus, Blood, TLR, Therapy, Clinical trial, Asthma, JAK, Dupilumab, Roflumilast, Polyp (medicine), TPD, Webcast, Patient, Psoriasis, TYK2, STAT6, Skin, Sinusitis, Pharmaceutical industry

As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.

Key Points: 
  • As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.
  • Kymera will share its immunology strategy, including market insights, program updates, new preclinical data and development timelines, at its virtual R&D Day this morning.
  • In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies.
  • Kymera will host a webcast to discuss its emerging immunology pipeline from 10:00 a.m. – 12:00 p.m.

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

Retrieved on: 
Saturday, November 4, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Patient, MDSC, Uveal melanoma, Fatigue, Nivolumab, T helper cell, DCR, Pancreas, PFS, Liver, Skin, FACS, SITC, NanoString Technologies, NK, Liver disease, Annual general meeting, Blood, TLR, Tumor microenvironment, University, Society, Progression-free survival, MD Anderson Cancer Center, Neoplasm, Society for Immunotherapy of Cancer, Medical imaging, Pharmaceutical industry, Immunotherapy, Cancer

The Progression-Free Survival (PFS), Disease Control Rate (DCR), and ctDNA molecular response data in PERIO-01 patients in combination with nivolumab are encouraging for UMLM and for other indications under development.

Key Points: 
  • The Progression-Free Survival (PFS), Disease Control Rate (DCR), and ctDNA molecular response data in PERIO-01 patients in combination with nivolumab are encouraging for UMLM and for other indications under development.
  • At the optimal biologic dose of SD-101 (2 mg) in combination with nivolumab (n=7), the median PFS was 11.7 months with an 81% DCR.
  • At the data cutoff as of September 29, 2023, 56 patients were enrolled, with each having received at least one dose of SD-101.
  • Dr. Katz added, “These data reflect additional validation of our innovative immunotherapy approach for liver and pancreas tumors.

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MDSC, Pancreatic tumor, Pressure, Pancreas, Liver, Perfusion, TLR9, Drug, FACS, SITC, Annual general meeting, Pancreatic cancer, Immunotherapy, TLR, Tumor microenvironment, University, Safety, Society, MD Anderson Cancer Center, Patient, Society for Immunotherapy of Cancer, Medical imaging, Medical device, Pharmaceutical industry, Cancer

In PERIO-03, SD-101 is delivered via PEDD with the TriSalus Infusion System® using a retrograde venous approach, leveraging established interventional radiology access techniques.

Key Points: 
  • In PERIO-03, SD-101 is delivered via PEDD with the TriSalus Infusion System® using a retrograde venous approach, leveraging established interventional radiology access techniques.
  • The TriSalus Infusion System has an expandable SmartValve® and can interface with standard invasive blood pressure transducers for continuous pressure monitoring during infusion of a therapeutic.
  • This is a first-in-human experience for use of PEDD and retrograde venous infusion for delivery of an immunologic agent into pancreatic tumors.
  • We are excited to continue enrolling patients in this study.”
    “These data offer additional validation of our innovative immunotherapy approach for pancreatic tumors.

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Wednesday, November 1, 2023
Female, Blood vessel, Maes, Kidney disease, Education, DCB, Freedom, MAE, TASC, Safety, Diabetes, Kaplan–Meier estimator, Research, Subgroup analysis, Meta-analysis, Pulmonary embolism, Death, BD, DVT, Detour, Clinical trial, Hypertension, Femoral vein, VIVA, TVR, Amputation, PTAB, Patient, Wynn Las Vegas, TLR, Medical imaging, Birth control, Pharmaceutical industry, Airline, SFA, Torus, EU

Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
  • A total of 1,005 patients at 74 investigational sites were treated with the Lutonix 035 DCB and were followed to 36 months.
  • Freedom from TLR at 12 months was 88.6%, and freedom from primary safety events at 30 days was 98.2%.
  • DETOUR clinical data demonstrate the clinical utility of this novel therapy in long femoropopliteal lesions.

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Society for Immunotherapy of Cancer, Neoplasm, Therapy, DC, TLR9, SITC, Immunotherapy, NK, CLEC2D, Society, Cancer, Patient, Myelocyte, TLR, Vaccine

WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023), held November 1-5.

Key Points: 
  • In vitro proof-of-concept for novel myeloid and B cell modulating anti-CLEC2D-TLR9 agonist conjugate program, a compelling immunotherapeutic approach to induce T and NK cell recruitment in tumors with otherwise low immunological activity
    WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023), held November 1-5.
  • Title: Anti CLEC2D-TLR9 agonist conjugate binds to and internalizes CLEC2D on myeloid cells, plasmacytoid DCs and B cells leading to robust TLR pathway activation and inflammatory cytokine production